This post was originally published on this site
Investing.com – Eli Lilly (NYSE:LLY) shares were trading weaker by 7% in premarket Monday after the company released disappointing data on a candidate drug for treating Alzheimer’s disease.
The share had closed 1.4% up Friday, giving the company a market cap of $199.43 billion.
The company said the findings from a stage 2 trial revealed the drug helped in slowing decline among people with early symptomatic forms of the disease. However, the results weren’t markedly better than for an earlier candidate drug, Solanezumab.
The company will provide more updates on its ‘TRAILBLAZER’ clinical trial program today.
